CHICAGO -- Many value investors look for stocks trading at Price/Earnings multiples below 15 and Price/Book multiples below 3. Combining these valuation measures with a Zacks Rank of #1 ("Strong Buy") or #2 ("Buy") helps to ensure that a stock is truly undervalued. The High Rank Value Profit Track strategy...
CHICAGO -- Many value investors look for stocks trading at Price/Earnings multiples below 15 and Price/Book multiples below 3. Combining these valuation measures with a Zacks Rank of #1 ("Strong Buy") or #2 ("Buy") helps to ensure that a stock is truly undervalued. The High Rank Value Profit Track strategy...
CHICAGO -- Zacks.com releases the latest list of Zacks Rank Buy Stocks. Everyday on Zacks.com, four stocks are selected based on how well they match the criteria for the four main schools of investing: Aggressive Growth, Growth & Income, Momentum and Value. The four Zacks Rank Buy stocks highlighted today...
CHICAGO -- Vivian Lewis offers international exposure through her global portfolios. Learn about Tenaris S.A. (NYSE:TS), Sanofi Aventis (NYSE:SNY), Magic Software (NASDAQ:MGIC), and M Systems Flashdisk (NASDAQ:FLSH). Vivian Lewis is the editor of the Global Investing newsletter. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84
CHICAGO -- Broaden your investing horizons with the following sampling of stocks from Vivian Lewis' Buy and Hold portfolio: Canadian National Railway (NYSE:CNI), Tenaris S.A. (NYSE:TS), Sanofi-Aventis (NYSE:SNY), Teva Pharmaceutical (NASDAQ:TEVA) and ICICI (NYSE:BN). Vivian Lewis is the editor of the Global Investing newsletter. Click here for the full story...
CHICAGO, Oct. 16 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks. Seven Summits Strategic Investments NewsBites are available to all investors at: http://www.go7now.com/nb/1016Y (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's Seven...
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sanofi-Aventis S.A. (NYSE: SNY), Highwoods Properties, Inc. (NYSE: HIW), SRS Labs,...
CHICAGO -- Zacks Equity Research highlights ConocoPhillips (NYSE: COP) as the Bull of the Day and Marriott International (NYSE: MAR) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Sanofi-Aventis ADR (NYSE: SNY), SRS Labs, Inc. (Nasdaq: SRSL) and Highwoods Properties (NYSE: HIW). ...
Stock markets Shares rallied as investors became more confident that a bailout plan for US banks could be revived. Banks were strong, with HSBC up 4.2 per cent and Standard Chartered jumping 8 per cent. Defensive drug stocks were also buoyant, led by Sanofi-Aventis and Roche,...
WORLD MARKETS Mining stock lost ground amid renewed economic growth worries and energy shares slid after a fall in crude oil prices. Steel maker ArcelorMittal dropped 4.5 per cent. Drug maker Sanofi-Aventis rose 2.5 per cent after news that Chris Viehbacher, head of North American pharmaceuticals...
CHICAGO, Sept. 10 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/091008A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts...
OncoVista Innovative Therapies, Inc. (OTCBB: OVIT) is a biopharmaceutical company engaged in the development andcommercialization of targeted cancer therapies and diagnostics. According to the Status Equity Research report published August 12, 2008,the world market for in vitro diagnostic IVD tests for cancer is growingat 11% annually and could reach $8...
OncoVista Innovative Therapies, Inc. (OTCBB: OVIT) is a biopharmaceutical company engaged in the development andcommercialization of targeted cancer therapies and diagnostics. According to the Status Equity Research report published August 12, 2008,the world market for in vitro diagnostic IVD tests for cancer is growingat 11% annually and could reach $8...
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), Sanofi-Aventis S.A. (NYSE: SNY), AstraZeneca (NYSE:...
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visteon Corp. (NYSE: VC), Sanofi-Aventis S.A. (NYSE: SNY), Big 5 Sporting...
M2 PRESSWIRE-13 February 2008-InvestorInstantMessaging: Has added Dyax Corp. to their watch list.C1994-2008 M2 COMMUNICATIONS LTD RDATE:13022008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you...
M2 PRESSWIRE-12 February 2008-Emerging Stock Report: Shares in DYAX Advance 23% on License DealC1994-2008 M2 COMMUNICATIONS LTD RDATE:12022008 Biopharm Sector- Dyax Corp. (NASDAQ: DYAX) and sanofi-aventis (EURONEXT: SAN) (NYSE: SNY) announced today that they have entered into agreements in...
M2 PRESSWIRE-7 January 2008-Market Review: Insomnia Review on Sanofi-aventisC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 Stocks lost ground Friday following the government's much anticipated report on the country's employment outlook which stated a weaker-than-expected job growth and a definite rise in...
Europe Stocks rose for the eighth time in 10 sessions as M&A activity boosted sentiment, while oil firms rallied on buoyant crude prices. Drug maker Sanofi-Aventis rose 2 per cent, adding to the previous session's gains on market talk Pfizer was looking to buy a stake in...
TRENTON, N.J. -- Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market, the Food and Drug Administration in recent months has rejected a slew of experimental drugs or delayed their approval and required more data. Besides keeping drugs some patients might desperately need...
Articles 2007-08-18
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
